{"title": "Un estudio para obtener informaci\u00f3n sobre un tratamiento repetido de 5 d\u00edas con los medicamentos del estudio (llamados nirmatrelvir/ritonavir) en personas de 12 a\u00f1os de edad o m\u00e1s con retorno de los s\u00edntomas de COVID-19 y positividad para el SARS-CoV-2 despu\u00e9s de finalizar el tratamiento con nirmatrelvir/ritonavir", "author": null, "url": "https://ichgcp.net/es/clinical-trials-registry/NCT05567952", "hostname": "ichgcp.net", "description": "El prop\u00f3sito de este estudio es conocer la seguridad y los efectos de nirmatrelvir/ritonavir para el tratamiento potencial del rebote de COVID-19.El estudio bus.... Registro de ensayos cl\u00ednicos. ICH GCP.", "sitename": "ichgcp.net", "date": "2022-10-03", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Un estudio para obtener informaci\u00f3n sobre un tratamiento repetido de 5 d\u00edas con los medicamentos del estudio (llamados nirmatrelvir/ritonavir) en personas de 12 a\u00f1os de edad o m\u00e1s con retorno de los s\u00edntomas de COVID-19 y positividad para el SARS-CoV-2 despu\u00e9s de finalizar el tratamiento con nirmatrelvir/ritonavir\n[Pfizer](https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer)\nUN ESTUDIO INTERVENCIONAL, DE EFICACIA Y SEGURIDAD, FASE 2, ALEATORIZADO, DOBLE CIEGO, DE 2 BRAZOS PARA INVESTIGAR UN CURSO REPETIDO DE 5 D\u00cdAS DE NIRMATRELVIR/RITONAVIR EN COMPARACI\u00d3N CON PLACEBO/RITONAVIR EN PARTICIPANTES DE AL MENOS 12 A\u00d1OS DE EDAD CON REBOTE DE COVID- 19 S\u00cdNTOMAS Y POSITIVIDAD DE LA PRUEBA R\u00c1PIDA DE ANT\u00cdGENO\nEl prop\u00f3sito de este estudio es conocer la seguridad y los efectos de nirmatrelvir/ritonavir para el tratamiento potencial del rebote de COVID-19.\nEl estudio busca participantes que:\n- Haber completado el tratamiento con nirmatrelvir/ritonavir\n- Tener un rebote en los s\u00edntomas de COVID-19\n- \u00bfSon SARS-CoV-2 (COVID-19) positivos?\nTodos los medicamentos del estudio se tomar\u00e1n 2 veces al d\u00eda por v\u00eda oral durante 5 d\u00edas. La primera dosis del medicamento del estudio se toma en la cl\u00ednica del estudio y el resto en casa.\nExaminaremos las experiencias de las personas que reciben los medicamentos del estudio a aquellas que no los reciben. Esto nos ayudar\u00e1 a determinar si los medicamentos del estudio son seguros y efectivos.\nLas personas que participen estar\u00e1n en este estudio durante aproximadamente 24 semanas. Los participantes inscritos deber\u00e1n visitar la cl\u00ednica del estudio al menos 8 veces durante el estudio.\nDescripci\u00f3n general del estudio\nEstado\nCondiciones\nIntervenci\u00f3n / Tratamiento\nTipo de estudio\nInscripci\u00f3n (Actual)\nFase\n- Fase 2\nContactos y Ubicaciones\nEstudio Contacto\n- Nombre: Pfizer CT.gov Call Center\n- N\u00famero de tel\u00e9fono: 1-800-718-1021\n- Correo electr\u00f3nico:\n[ClinicalTrials.gov_Inquiries@pfizer.com](mailto:ClinicalTrials.gov_Inquiries@pfizer.com?subject=NCT05567952, C4671042, A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir)\nUbicaciones de estudio\n-\nCanad\u00e1\n-\nOntario\n-\nGuelph, Ontario, Canad\u00e1, N1H 1B1\n- Dawson Clinical Research\n-\nHamilton, Ontario, Canad\u00e1, L8M 1K7\n- Hamilton Medical Research Group\n-\nOshawa, Ontario, Canad\u00e1, L1G 4T3\n- Medical Trust Clinics\n-\nWinchester, Ontario, Canad\u00e1, K0C 2K0\n- Winchester District Memorial Hospital\n-\n-\n-\nEstados Unidos\n-\nArizona\n-\nMesa, Arizona, Estados Unidos, 85210\n- The Institute for Liver Health dba Arizona Clinical Trials\n-\nPhoenix, Arizona, Estados Unidos, 85031\n- Abby's Research institute\n-\nSurprise, Arizona, Estados Unidos, 85378\n- Epic Medical Research - Surprise\n-\n-\nCalifornia\n-\nAnaheim, California, Estados Unidos, 92806\n- Smart Cures Clinical Research\n-\nCanoga Park, California, Estados Unidos, 91303\n- Hope Clinical Research, Inc.\n-\nFullerton, California, Estados Unidos, 92835\n- Ascada Research\n-\nLa Mesa, California, Estados Unidos, 91942\n- Paradigm Clinical Research Centers, Inc\n-\nLong Beach, California, Estados Unidos, 90806\n- CVS Health - 8876 - Long Beach\n-\nNorth Hollywood, California, Estados Unidos, 91606\n- Carbon Health - North Hollywood - NoHo West\n-\n-\nColorado\n-\nWheat Ridge, Colorado, Estados Unidos, 80033\n- Paradigm Clinical Research Centers, Inc\n-\n-\nDistrict of Columbia\n-\nWashington, District of Columbia, Estados Unidos, 20011\n- Emerson Clinical Research Institute\n-\n-\nFlorida\n-\nBrandon, Florida, Estados Unidos, 33511\n- Palm Harbor Dermatology PA d/b/a TrueBlue Clinical Research\n-\nCoral Gables, Florida, Estados Unidos, 33134\n- Herco Medical and Research Center Inc\n-\nHialeah, Florida, Estados Unidos, 33016\n- Sweet Hope Research Specialty, Inc\n-\nHialeah Gardens, Florida, Estados Unidos, 33018\n- Unlimited Medical Research Group\n-\nMiami, Florida, Estados Unidos, 33126\n- LCC Medical Research Institute\n-\nMiami, Florida, Estados Unidos, 33126\n- Premium Medical Research Corp\n-\nMiami, Florida, Estados Unidos, 33176\n- Entrust Clinical Research\n-\nMiami, Florida, Estados Unidos, 33176\n- Reed Medical Research\n-\nMiami, Florida, Estados Unidos, 33165\n- Reliant Medical Research\n-\nMiami, Florida, Estados Unidos, 33135\n- South Florida Research Center\n-\nMiami, Florida, Estados Unidos, 33185\n- Kendall South Medical Center\n-\nMiami, Florida, Estados Unidos, 33175\n- Innova Pharma Research\n-\nMiami, Florida, Estados Unidos, 33135\n- Global Health Clinical Trials\n-\nMiami Gardens, Florida, Estados Unidos, 33014\n- Pro-Care Research Center, Corp.\n-\nOrlando, Florida, Estados Unidos, 32808\n- Omega Research Orlando\n-\nPompano Beach, Florida, Estados Unidos, 33064\n- NAPA Research\n-\nSaint Petersburg, Florida, Estados Unidos, 33705\n- GCP Research, Global Clinical professionals\n-\nSaint Petersburg, Florida, Estados Unidos, 33710\n- Theia Clinical Research - 5th Avenue North\n-\nSpring Hill, Florida, Estados Unidos, 34609\n- Asclepes Research Center - Spring Hill\n-\nTampa, Florida, Estados Unidos, 33615\n- Santos Research Center\n-\nTampa, Florida, Estados Unidos, 33609\n- Palm Harbor Dermatology PA d/b/a TrueBlue Clinical Research\n-\nWinter Park, Florida, Estados Unidos, 32789\n- Clinical Site Partners, LLC dba Flourish Research\n-\n-\nIdaho\n-\nBlackfoot, Idaho, Estados Unidos, 83221\n- Bingham Memorial Hospital\n-\n-\nIllinois\n-\nChicago, Illinois, Estados Unidos, 60637\n- University of Chicago Medical Center\n-\n-\nMaryland\n-\nElkridge, Maryland, Estados Unidos, 21075\n- Centennial Medical Group\n-\n-\nMassachusetts\n-\nWorcester, Massachusetts, Estados Unidos, 01655\n- University of Massachusetts Chan Medical School\n-\n-\nMichigan\n-\nBay City, Michigan, Estados Unidos, 48706\n- Great Lakes Research Group, Inc.\n-\nDetroit, Michigan, Estados Unidos, 48201\n- C.S. Mott Clinical Research Center (CRC)\n-\nRoyal Oak, Michigan, Estados Unidos, 48073\n- Beaumont Infectious Diseases Research\n-\n-\nMississippi\n-\nOlive Branch, Mississippi, Estados Unidos, 38654\n- Olive Branch Family Medical Center\n-\n-\nMontana\n-\nButte, Montana, Estados Unidos, 59701\n- Mercury Street Medical Group, PLLC\n-\n-\nNevada\n-\nLas Vegas, Nevada, Estados Unidos, 89109\n- Excel Clinical Research, LLC\n-\n-\nNew Jersey\n-\nEast Brunswick, New Jersey, Estados Unidos, 08816\n- CVS Health - Site 02815 East Brunswick\n-\nNeptune, New Jersey, Estados Unidos, 07753\n- Hackensack Meridian Jersey Shore University Medical Center\n-\n-\nNew York\n-\nBronx, New York, Estados Unidos, 10467\n- Montefiore Medical Center\n-\n-\nNorth Carolina\n-\nCharlotte, North Carolina, Estados Unidos, 28208\n- OnSite Clinical Solutions\n-\nWilmington, North Carolina, Estados Unidos, 28401\n- Accellacare - Wilmington\n-\n-\nOhio\n-\nColumbus, Ohio, Estados Unidos, 43214\n- WellNow Urgent Care and Research - Columbus\n-\n-\nOregon\n-\nEugene, Oregon, Estados Unidos, 97404\n- Willamette Valley Clinical Studies\n-\n-\nPennsylvania\n-\nBeaver, Pennsylvania, Estados Unidos, 15009\n- Heritage Valley Multispecialty Group, Inc\n-\n-\nTennessee\n-\nUnion City, Tennessee, Estados Unidos, 38261\n- Premier Primary Care\n-\n-\nTexas\n-\nAndrews, Texas, Estados Unidos, 79714\n- Nayak Research, LLC\n-\nBrownsville, Texas, Estados Unidos, 78526\n- Headlands Research - Brownsville\n-\nDallas, Texas, Estados Unidos, 75235\n- Southwest Family Medicine Associates\n-\nHouston, Texas, Estados Unidos, 77057\n- Next Level Urgent Care\n-\nHouston, Texas, Estados Unidos, 77021\n- Next Innovative Clinical Research\n-\nHumble, Texas, Estados Unidos, 77338\n- Accurate Clinical Research - East Humble\n-\nSan Antonio, Texas, Estados Unidos, 78215\n- Sun Research Institute\n-\n-\nWashington\n-\nRedmond, Washington, Estados Unidos, 98052\n- Eastside Research Associates\n-\n-\n-\nGrecia\n-\n-\nAthens, Grecia, 11527\n- General Hospital of Athens \"Laiko\"\n-\nThessaloniki, Grecia, 54636\n- AHEPA University General Hospital of Thessaloniki\n-\n-\nAttica\n-\nAthens, Attica, Grecia, 11527\n- Thoracic General Hospital of Athens \"I Sotiria\"\n-\n-\nAttik\u00ed\n-\nAthens, Attik\u00ed, Grecia, 106 76\n- Evangelismos General Hospital of Athens\n-\nAthens, Attik\u00ed, Grecia, 115 28\n- Alexandra General Hospital of Athens\n-\n-\n-\nItalia\n-\n-\nPavia, Italia, 27100\n- Fondazione IRCCS Policlinico San Matteo\n-\n-\nLombardia\n-\nMilano, Lombardia, Italia, 20122\n- Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico\n-\n-\nMilano\n-\nMilan, Milano, Italia, 20157\n- ASST Fatebenefratelli Sacco\n-\n-\nSicilia\n-\nPalermo, Sicilia, Italia, 90129\n- A.O.U. Policlinico Paolo Giaccone\n-\n-\n-\nTaiw\u00e1n\n-\n-\nTaichung, Taiw\u00e1n, 407\n- Taichung Veterans General Hospital\n-\nTaipei, Taiw\u00e1n, 10002\n- National Taiwan University Hospital\n-\nTaipei, Taiw\u00e1n, 11217\n- Taipei Veterans General Hospital\n-\n-\nNEW Taipei\n-\nNew Taipei City, NEW Taipei, Taiw\u00e1n, 220\n- Far Eastern Memorial Hospital\n-\n-\nCriterios de participaci\u00f3n\nCriterio de elegibilidad\nEdades elegibles para estudiar\nAcepta Voluntarios Saludables\nDescripci\u00f3n\nCriterios de inclusi\u00f3n:\n- Documentaci\u00f3n del tratamiento con nirmatrelvir/ritonavir con cumplimiento del 100 % informado por el paciente. Alivio o resoluci\u00f3n de los s\u00edntomas de COVID-19 seguido de un empeoramiento (rebote) de los signos/s\u00edntomas despu\u00e9s de completar un ciclo inicial de 5 d\u00edas de nirmatrelvir/ritonavir\n- Inicio del rebote en los s\u00edntomas de COVID-19 dentro de las 2 semanas (14 d\u00edas) despu\u00e9s de completar el ciclo inicial de 5 d\u00edas de nirmatrelvir/ritonavir.\n- Aparici\u00f3n de signos/s\u00edntomas de rebote atribuibles a COVID-19 dentro de las 48 horas previas a la aleatorizaci\u00f3n y \u22651 signo/s\u00edntoma atribuible a COVID-19 presente el d\u00eda de la aleatorizaci\u00f3n.\n- Infecci\u00f3n por SARS-CoV-2 seg\u00fan lo determinado por prueba r\u00e1pida de ant\u00edgeno dentro de las 24 horas previas a la aleatorizaci\u00f3n\n- Al menos 1 caracter\u00edstica o condici\u00f3n m\u00e9dica subyacente asociada con un mayor riesgo de desarrollar una enfermedad grave por COVID-19.\nCriterio de exclusi\u00f3n:\n- Necesidad actual de hospitalizaci\u00f3n, hospitalizado por la infecci\u00f3n por COVID-19 o necesidad anticipada de hospitalizaci\u00f3n dentro de las 24 horas posteriores a la aleatorizaci\u00f3n\n- Antecedentes de enfermedad hep\u00e1tica cr\u00f3nica grave.\n- Recibe di\u00e1lisis o tiene una tasa de filtraci\u00f3n glomerular estimada (eGFR) espec\u00edfica para la edad conocida o una depuraci\u00f3n de creatinina estimada (eCrCl)\n- Saturaci\u00f3n de ox\u00edgeno de\n- Inmunocomprometidos.\n- Uso actual de cualquier medicamento concomitante prohibido\n- Mujeres embarazadas y\nPlan de estudios\n\u00bfC\u00f3mo est\u00e1 dise\u00f1ado el estudio?\nDetalles de dise\u00f1o\n- Prop\u00f3sito principal: Tratamiento\n- Asignaci\u00f3n: Aleatorizado\n- Modelo Intervencionista: Asignaci\u00f3n paralela\n- Enmascaramiento: Triple\nArmas e Intervenciones\n|\n|\nGrupo de participantes/brazo\n|\n|\nIntervenci\u00f3n / Tratamiento\n|\n|\nExperimental: nirmatrelvir m\u00e1s ritonavir durante 5 d\u00edas\nNirmatrelvir (2 tabletas) m\u00e1s ritonavir (1 c\u00e1psula) se administrar\u00e1n por v\u00eda oral cada 12 horas durante 5 d\u00edas.\n|\n|\nLos participantes recibir\u00e1n 2 tabletas de nirmatrelvir cada 12 horas\nLos participantes recibir\u00e1n 1 c\u00e1psula de ritonavir cada 12 horas\n|\n|\nOtro: placebo m\u00e1s ritonavir durante 5 d\u00edas\nse administrar\u00e1 placebo (2 tabletas) m\u00e1s ritonavir (1 c\u00e1psula) por v\u00eda oral cada 12 horas durante 5 d\u00edas\n|\n|\nLos participantes recibir\u00e1n 1 c\u00e1psula de ritonavir cada 12 horas\nLos participantes recibir\u00e1n 2 tabletas de placebo de nirmatrelvir cada 12 horas. Un placebo no contiene ning\u00fan medicamento, pero se parece al medicamento que se est\u00e1 estudiando.\n\u00bfQu\u00e9 mide el estudio?\nMedidas de resultado primarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nEl cambio en el nivel de ARN viral del SARS-CoV-2 medido en hisopos nasofar\u00edngeos (NP)\nPeriodo de tiempo: L\u00ednea de base al d\u00eda 5\n|\n|\nComparar el efecto de nirmatrelvir/ritonavir con placebo/ritonavir en el nivel de ARN viral en hisopos nasofar\u00edngeos en participantes con COVID-19 de leve a moderado.\n|\n|\nL\u00ednea de base al d\u00eda 5\nMedidas de resultado secundarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nTiempo hasta 2 resultados negativos consecutivos de la prueba r\u00e1pida de ant\u00edgeno obtenidos con al menos 24 horas de diferencia hasta el d\u00eda 28\nPeriodo de tiempo: Del d\u00eda 1 al d\u00eda 28\n|\n|\nComparar el efecto de nirmatrelvir/ritonavir con placebo/ritonavir sobre la duraci\u00f3n de la excreci\u00f3n viral.\n|\n|\nDel d\u00eda 1 al d\u00eda 28\n|\n|\nTiempo hasta el alivio sostenido de todos los signos y s\u00edntomas definidos como el primero de dos d\u00edas consecutivos cuando los s\u00edntomas calificados como moderados/graves al inicio se califican como leves/ausentes y los s\u00edntomas calificados como leves/ausentes al inicio se califican como ausentes.\nPeriodo de tiempo: Del d\u00eda 1 al d\u00eda 28\n|\n|\nComparar el efecto de nirmatrelvir/ritonavir con placebo/ritonavir sobre la duraci\u00f3n y la gravedad de los signos y s\u00edntomas en participantes con COVID-19 leve a moderado.\n|\n|\nDel d\u00eda 1 al d\u00eda 28\n|\n|\nIncidencia de eventos adversos emergentes del tratamiento.\nPeriodo de tiempo: Del d\u00eda 1 a la semana 24\n|\n|\nDescribir la seguridad y la tolerabilidad de nirmatrelvir/ritonavir en participantes con COVID-19 de leve a moderado.\n|\n|\nDel d\u00eda 1 a la semana 24\n|\n|\nIncidencia de eventos adversos graves y eventos adversos que conducen a la interrupci\u00f3n.\nPeriodo de tiempo: Del d\u00eda 1 a la semana 24\n|\n|\nDescribir la seguridad y la tolerabilidad de nirmatrelvir/ritonavir en participantes con COVID-19 de leve a moderado.\n|\n|\nDel d\u00eda 1 a la semana 24\nColaboradores e Investigadores\nPatrocinador\nInvestigadores\n- Director de estudio: Pfizer CT.gov Call Center, Pfizer\nPublicaciones y enlaces \u00fatiles\nFechas de registro del estudio\nFechas importantes del estudio\nInicio del estudio (Actual)\nFinalizaci\u00f3n primaria (Estimado)\nFinalizaci\u00f3n del estudio (Estimado)\nFechas de registro del estudio\nEnviado por primera vez\nPrimero enviado que cumpli\u00f3 con los criterios de control de calidad\nPublicado por primera vez (Actual)\nActualizaciones de registros de estudio\n\u00daltima actualizaci\u00f3n publicada (Actual)\n\u00daltima actualizaci\u00f3n enviada que cumpli\u00f3 con los criterios de control de calidad\n\u00daltima verificaci\u00f3n\nM\u00e1s informaci\u00f3n\nT\u00e9rminos relacionados con este estudio\nPalabras clave\nT\u00e9rminos MeSH relevantes adicionales\n-\n[Infecciones por coronavirus](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronavirus%20Infections)\n-\n[Infecciones por coronaviridae](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronaviridae%20Infections)\n-\n[Infecciones por Nidovirales](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Nidovirales%20Infections)\n-\n[Infecciones por virus de ARN](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=RNA%20Virus%20Infections)\n-\n[Enfermedades virales](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Virus%20Diseases)\n-\n[Infecciones](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Infections)\n-\n[Infecciones del Tracto Respiratorio](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Infections)\n-\n[Enfermedades de las v\u00edas respiratorias](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases)\n-\n[Neumon\u00eda Viral](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pneumonia%2C%20Viral)\n-\n[Neumon\u00eda](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pneumonia)\n-\n[Enfermedades pulmonares](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Lung%20Diseases)\n-\n[COVID-19](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=COVID-19)\n-\n[Mecanismos moleculares de acci\u00f3n farmacol\u00f3gica](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action)\n-\n[Agentes antiinfecciosos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Anti-Infective%20Agents)\n-\n[Agentes Antivirales](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antiviral%20Agents)\n-\n[Inhibidores de enzimas](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors)\n-\n[Agentes Anti-VIH](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Anti-HIV%20Agents)\n-\n[Agentes antirretrovirales](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Anti-Retroviral%20Agents)\n-\n[Inhibidores de la proteasa](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Protease%20Inhibitors)\n-\n[Inhibidores del citocromo P-450 CYP3A](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cytochrome%20P-450%20CYP3A%20Inhibitors)\n-\n[Inhibidores de enzimas del citocromo P-450](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cytochrome%20P-450%20Enzyme%20Inhibitors)\n-\n[Inhibidores de la proteasa del VIH](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=HIV%20Protease%20Inhibitors)\n-\n[Inhibidores de la proteasa viral](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Viral%20Protease%20Inhibitors)\n-\n[Ritonavir](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Ritonavir)\n-\n[Nirmatrelvir](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Nirmatrelvir)\nOtros n\u00fameros de identificaci\u00f3n del estudio\n- C4671042\n- 2022-002827-36 (N\u00famero EudraCT)\nPlan de datos de participantes individuales (IPD)\n\u00bfPlanea compartir datos de participantes individuales (IPD)?\nDescripci\u00f3n del plan IPD\nInformaci\u00f3n sobre medicamentos y dispositivos, documentos del estudio\nEstudia un producto farmac\u00e9utico regulado por la FDA de EE. UU.\nEstudia un producto de dispositivo regulado por la FDA de EE. UU.\nEsta informaci\u00f3n se obtuvo directamente del sitio web\n[clinicaltrials.gov](https://clinicaltrials.gov) sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comun\u00edquese con [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Tan pronto como se implemente un cambio en [clinicaltrials.gov](https://clinicaltrials.gov), tambi\u00e9n se actualizar\u00e1 autom\u00e1ticamente en nuestro sitio web. .\nEnsayos cl\u00ednicos sobre COVID-19\n-\nNCT06042530ReclutamientoDeterioro Cognitivo | Condici\u00f3n posterior a COVID-19 | Fatiga Mental\n-\nNCT06039449Reclutamiento\n-\nNCT06038617A\u00fan no reclutandoFiebre | Fiebre despu\u00e9s de la vacunaci\u00f3n | Convulsiones Fiebre\n-\nNCT06038682Reclutamiento\n-\nNCT06036134A\u00fan no reclutandoSalud Conocimiento, Actitudes, Pr\u00e1ctica | Pandemia de COVID-19 | Enfermedades prevenibles por vacunaci\u00f3n | Comportamiento relacionado con la salud | Narraci\u00f3n\n-\nNCT06036251A\u00fan no reclutandoEstr\u00e9s | Estr\u00e9s, Emocional | Pandemia de COVID-19 | Reacci\u00f3n de estr\u00e9s\n-\nNCT06030414A\u00fan no reclutando\n-\nNCT06032000A\u00fan no reclutando\n[Un estudio de fase 1 para evaluar la seguridad, reactogenicidad e inmunogenicidad de una vacuna de refuerzo contra el SARS-CoV-2 (LEM-mR203) en adultos sanos](https://ichgcp.net/es/clinical-trials-registry/NCT06032000)Contagio de COVID-19 | Reacci\u00f3n adversa a la vacuna COVID-19\n-\nNCT06027229A\u00fan no reclutando\n[Inmunogenicidad humoral y celular recombinante adicional de COVID-19 en poblaciones inmunodeprimidas](https://ichgcp.net/es/clinical-trials-registry/NCT06027229)COVID-19 | Inmunosupresi\u00f3n\n-\nNCT06027255A\u00fan no reclutandoCOVID largo | Disfunci\u00f3n auton\u00f3mica | POTS - S\u00edndrome de taquicardia ortost\u00e1tica postural\nEnsayos cl\u00ednicos sobre nirmatrelvir\n-\n-\nNCT05997485A\u00fan no reclutandoTratamiento farmacol\u00f3gico COVID-19\n-\nNCT05938140Reclutamiento\n[Eficiencia y seguridad de Paxlovid para pacientes con COVID-19 con enfermedad renal cr\u00f3nica grave (ESPTCSCKD)](https://ichgcp.net/es/clinical-trials-registry/NCT05938140)COVID-19 | Insuficiencia Renal Cr\u00f3nica\n-\nNCT05894603Reclutamiento\n-\nNCT05852873A\u00fan no reclutando\n[PRUEBA LARGA DE PREVENCI\u00d3N DE COVID-19 DE PAXLOVID CON RECLUTAMIENTO EN LA COMUNIDAD EN NORUEGA (PanoramicNOR)](https://ichgcp.net/es/clinical-trials-registry/NCT05852873)COVID-19 | Infecci\u00f3n por SARS-CoV2 | Condici\u00f3n posterior a COVID-19, no especificada\n-\nNCT05823896ReclutamientoCOVID-19 | S\u00edndrome Post-COVID-19 | COVID largo | Largo Covid19 | Condici\u00f3n posterior a COVID-19 | S\u00edndrome Post-COVID | Condici\u00f3n posterior a COVID-19, no especificada | POTS - S\u00edndrome de taquicardia ortost\u00e1tica postural | Inflamaci\u00f3n posinfecciosa | Trastorno posinfeccioso\n-\nNCT05749445ReclutamientoPacientes hospitalizados\n-\nNCT05697055Reclutamiento\n-\nNCT05668091Reclutamiento\n-\nNCT05638919Reclutamiento", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/es", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/ich-e-group-of-guidelines", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/events", "https://ichgcp.net/es/clinical-trials-registry/publications", "https://ichgcp.net/es/clinical-trials-registry/researchers", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/clinical-trials-registry/NCT05567952", "https://telegram.me/share/url?url=https://ichgcp.net/es/clinical-trials-registry/NCT05567952&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/es/clinical-trials-registry/NCT05567952", "https://ichgcp.net/es", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=COVID-19", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=nirmatrelvir", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=ritonavir", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=placebo%20for%20nirmatrelvir", "mailto:ClinicalTrials.gov_Inquiries@pfizer.com?subject=NCT05567952, C4671042, A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=nirmatrelvir", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=ritonavir", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=ritonavir", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=placebo%20for%20nirmatrelvir", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://pmiform.com/clinical-trial-info-request?StudyID=C4671042", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Paxlovid", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Nirmatrelvir", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Severe%20acute%20respiratory%20syndrome%20coronavirus%202%20%28SARS-CoV-2%29", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Coronavirus%20disease%202019%20%28COVID-19%29", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=COVID-19%20rebound", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronavirus%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronaviridae%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Nidovirales%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=RNA%20Virus%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Virus%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pneumonia%2C%20Viral", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pneumonia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Lung%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=COVID-19", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Anti-Infective%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Antiviral%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Enzyme%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Anti-HIV%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Anti-Retroviral%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Protease%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cytochrome%20P-450%20CYP3A%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cytochrome%20P-450%20Enzyme%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=HIV%20Protease%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Viral%20Protease%20Inhibitors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Ritonavir", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Nirmatrelvir", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/es/clinical-trials-registry/NCT06042530", "https://ichgcp.net/es/clinical-trials-registry/NCT06039449", "https://ichgcp.net/es/clinical-trials-registry/NCT06038617", "https://ichgcp.net/es/clinical-trials-registry/NCT06038682", "https://ichgcp.net/es/clinical-trials-registry/NCT06036134", "https://ichgcp.net/es/clinical-trials-registry/NCT06036251", "https://ichgcp.net/es/clinical-trials-registry/NCT06030414", "https://ichgcp.net/es/clinical-trials-registry/NCT06032000", "https://ichgcp.net/es/clinical-trials-registry/NCT06027229", "https://ichgcp.net/es/clinical-trials-registry/NCT06027255", "https://ichgcp.net/es/clinical-trials-registry/NCT06016556", "https://ichgcp.net/es/clinical-trials-registry/NCT05997485", "https://ichgcp.net/es/clinical-trials-registry/NCT05938140", "https://ichgcp.net/es/clinical-trials-registry/NCT05894603", "https://ichgcp.net/es/clinical-trials-registry/NCT05852873", "https://ichgcp.net/es/clinical-trials-registry/NCT05823896", "https://ichgcp.net/es/clinical-trials-registry/NCT05749445", "https://ichgcp.net/es/clinical-trials-registry/NCT05697055", "https://ichgcp.net/es/clinical-trials-registry/NCT05668091", "https://ichgcp.net/es/clinical-trials-registry/NCT05638919", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Orphanetics%2BPharma%2BEntwicklungs%2BGmbH", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pediatric%2BOrthopaedic%2BSociety%2Bof%2BNorth%2BAmerica", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Medtronic%2BSurgical%2BTechnologies", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=European%2BSociety%2Bof%2BHuman%2BReproduction%2Band%2BEmbryology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidade%2Bde%2BLisboa%252C%2BPortugal", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidad%2Bdel%2BZulia", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jos%25C3%25A9phine%2BSOLTANI%252C%2BCardiology%2Bdepartment%252C%2BVersailles%2BHospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Center%2Bfor%2BIndustrial%2BTechnological%2BDevelopment%2Bof%2BSpain", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=SeeCure%2BLLC", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Kaneka%2BAmericas%2BHolding%2BInc.", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BAdrenal%2BCortical", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stage%2BI%2BGallbladder%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ankle%2BArthroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Esophageal%2BResection%2BCandidates", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ultrasound%2BEvaluation", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Post-traumatic%2BAnosmia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Malignant%2BNeoplasm%2Bof%2BRespiratory%2Band%2BIntrathoracic%2BOrgan%2BCarcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Colon%2BMalignant%2BTumor", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Postneoadjuvant%2BTherapy%2BStage%2BI%2BGastric%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Cushing%2527s%2BSyndrome%2BI", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=MK-8521%2B100%25CE%25BCg", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Transplant%2B2%2BMelphalan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=20mg%2BAzilsartan%2BTablets", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Alpelisib%2B150%2BMG%2BOral%2BTablet%2B%255BPiqray%255D", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Teicoplanin%2BSandoz%2B200%2Bmg%2Bpowder%2Band%2Bsolvent%2Bfor%2Bsolution%2Bfor%2Binjection%2Bor%2Binfusion%2Bor%2Boral%2Bsolution.", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Injectafer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Brimonidine%2Btartrate%2Bophthalmic%2Bsolution%2B0.025%2525%2B%2528n%2B%253D%2B56%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Valacyclovir%2Barrow", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Pilocarpine%2B1.25%2525%2BEye%2Bdrop", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oral%2BGlucose%2BGel", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/cro-list/country/austria", "https://ichgcp.net/es/cro-list/country/belarus", "https://ichgcp.net/es/cro-list/country/belgium", "https://ichgcp.net/es/cro-list/country/ecuador", "https://ichgcp.net/es/cro-list/country/gabon", "https://ichgcp.net/es/cro-list/country/israel", "https://ichgcp.net/es/cro-list/country/latvia", "https://ichgcp.net/es/cro-list/country/malaysia", "https://ichgcp.net/es/cro-list/country/mongolia", "https://ichgcp.net/es/cro-list/country/romania", "https://ichgcp.net/es/cro-list/country/switzerland", "https://ichgcp.net/es/cro-list/country/united_kingdom", "https://ichgcp.net/es/cro-list/country/usa", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/cro-list/country/usa/company/sekisui_xenotech", "https://ichgcp.net/es/cro-list/country/usa/company/tms_biosceinces", "https://ichgcp.net/es/cro-list/country/usa/company/clinfinity", "https://ichgcp.net/es/cro-list/country/usa/company/davita_clinical_research", "https://ichgcp.net/es/cro-list/country/usa/company/genscript", "https://ichgcp.net/es/cro-list/country/usa/company/concentrics_research", "https://ichgcp.net/es/cro-list/country/usa/company/at_clinical_systems", "https://ichgcp.net/es/cro-list/country/usa/company/emissary", "https://ichgcp.net/es/cro-list/country/usa/company/advanced_clinical_services_llc", "https://ichgcp.net/es/cro-list/country/usa/company/sofpromed", "https://ichgcp.net/es/cro-list/country/usa", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/es", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/es/sitemap", "https://ichgcp.net/es/contact-us", "https://ichgcp.net/es/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT05567952", "https://ichgcp.net/de/clinical-trials-registry/NCT05567952", "https://ichgcp.net/clinical-trials-registry/NCT05567952", "https://ichgcp.net/es/clinical-trials-registry/NCT05567952", "https://ichgcp.net/fr/clinical-trials-registry/NCT05567952", "https://ichgcp.net/it/clinical-trials-registry/NCT05567952", "https://ichgcp.net/hu/clinical-trials-registry/NCT05567952", "https://ichgcp.net/nl/clinical-trials-registry/NCT05567952", "https://ichgcp.net/no/clinical-trials-registry/NCT05567952", "https://ichgcp.net/pl/clinical-trials-registry/NCT05567952", "https://ichgcp.net/pt/clinical-trials-registry/NCT05567952", "https://ichgcp.net/fi/clinical-trials-registry/NCT05567952", "https://ichgcp.net/sv/clinical-trials-registry/NCT05567952", "https://ichgcp.net/cs/clinical-trials-registry/NCT05567952", "https://ichgcp.net/ru/clinical-trials-registry/NCT05567952", "https://ichgcp.net/ja/clinical-trials-registry/NCT05567952", "https://ichgcp.net/zh/clinical-trials-registry/NCT05567952", "https://ichgcp.net/ko/clinical-trials-registry/NCT05567952", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}